PharmaTimes December 2, 2024
John Pinching

Race to create first oral drug for obesity intensifies

The competition to gain approval for the first oral GLP-1R drug for obesity is heating up, with four phase 3 trials currently in progress, according to GlobalData.

Obesity, defined as an excessive accumulation of body fat, has reached epidemic levels. Predictions suggest that by 2030, half of all US adults will be obese, according to the New England Journal of Medicine. This trend presents a lucrative opportunity for drugmakers, particularly in the market for oral GLP-1R products.

Jasper Morley, Pharma Analyst at GlobalData, explains the significance: “Novo Nordisk and Eli Lilly are leading the charge to expand their GLP-1R portfolios and secure their positions as frontrunners in the oral GLP-1R for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Pharma / Biotech
Related Articles:
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
A Biologist Explains The ‘Weird’ Habits Of People Who Live To 100+ Years Old
U.S. Health Care Spending Reaches $4.9 Trillion
Medicaid spending on weight loss, diabetes drugs up 500% since 2019: 5 numbers to know
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

Share This Article